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Background GH insensitivity (GHI) encompasses growth failure, low serum IGF-1 and 
normal/elevated serum growth hormone (GH) (basal level >5μg/L and/or peak on 
provocation testing >10μg/L). In a significant number of children the molecular cause is 
unknown. 
Objective To investigate the genetic etiology of GHI in a cohort of children by candidate 
gene (CGS) and whole exome (WES) sequencing.    
Methods 109 patients (61 M, median age 6.5 yr [range 0.4-17.0]) with a phenotype 
consistent with GHI (mean height SDS -4.8; mean IGF-1 SDS -2.7) were accepted for 
genetic investigation since 2008. CGS was undertaken for GH-IGF1 axis [GHR, STAT5B, 
IGFALS, IGF1] and 3M [CUL7, CCDC8, OBSL1] genes and WES was performed in 
unsolved cases (to date, 53 patients). A bioinformatic pipeline was developed to 
interrogate the WES data and identify potential causative genetic variants. 
Results CGS identified homozygous mutations in the following genes in 36 patients: GHR 
[26], IGFALS [3], OBSL1 [6] and CUL7 [1]. WES identified changes in 13 patients: 
compound heterozygous IGFALS [1], homozygous GHR [5], heterozygous PTPN11 [2], 
homozygous CCDC8 [3], homozygous CUL7 [1], and heterozygous SOS1 [1]. 14 of these 
genetic variants are novel. In 2 subjects who were small for gestational age (birth weight 
SDS -2.3 and -1.8) hypomethylation in the imprinting control region 11p15 or mUPD7 was 
demonstrated confirming Silver Russell Syndrome (SRS). Mining the WES data of patients 
without a genetic diagnosis identified 24 candidate genes having deleterious variants in 
more than one GHI patient.   
Conclusions A genetic diagnosis was obtained in 51 (47%) patients. These included 14 
novel variants. Importantly, WES identified 13 mutations in known genes, which had not 
been detected on CGS. Diagnoses with phenotypes overlapping with GHI included SRS, 
3M and Noonan syndrome. Variants in novel genes with potential impact on growth have 
been identified and are under further investigation.  
 
 
